Is compounded semaglutide still legal and safe?

Yes, within limits. Compounded semaglutide is still legal in 2026 when a state-licensed pharmacy makes it for an individual patient with a prescription, but the FDA declared the shortage over on February 21, 2025, and the rules have tightened since. It is not Wegovy or Ozempic, and not a generic of either. It isn’t FDA-approved and the FDA does not review it for safety, effectiveness or quality, so you are relying on the prescriber and the pharmacy rather than FDA review.

What changed: a timeline

During the shortage, pharmacies had more room to compound semaglutide. Once the FDA declared it resolved, that room closed in stages (FDA).

What’s allowed in 2026

503A pharmacies

503A pharmacies are state-licensed pharmacies (and physicians) that compound for individual patients. Under the FDA’s April 1, 2026 reminder, they may compound semaglutide only for an individual patient with a prescription. They may not compound “regularly or in inordinate amounts” anything that is essentially a copy, which the FDA generally defines as the same active ingredient as a commercially available drug, in the same, similar or easily substitutable strength, given the same way.

There are two carve-outs worth knowing. A prescriber can document a significant difference for a specific patient. And the FDA does not currently intend to act on compounders that fill 4 or fewer such prescriptions per calendar month.

Adding ingredients doesn’t get around the rule on its own. The FDA’s own example is semaglutide plus B12 at strengths within 10% of the commercial product, which can still count as essentially a copy.

503B outsourcing facilities

503B outsourcing facilities may compound from bulk ingredients only if the drug is on the 503B bulks list or the FDA shortage list. Semaglutide is on neither. On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the bulks list, finding “no clinical need,” with comments due June 29, 2026.

In plain terms, legal compounded semaglutide today comes from a 503A pharmacy, made for you by name on a prescription. If it uses the same ingredient, strength and route as an approved product, the pharmacy can’t make it regularly or in large amounts unless your prescriber documents a significant difference for you.

How the FDA is enforcing the rules

Much of the enforcement has targeted how these drugs are marketed. The September 2025 letters centered on claims of sameness with FDA-approved drugs. The March 2026 letters cited “claims implying sameness with FDA-approved products” and selling under the telehealth firm’s own name, which implies the firm is the compounder. By March 12, 2026, more than 70 telehealth companies had been warned in six months (STAT).

The February 2026 announcement went further. The FDA said it may pursue seizure and injunction “without further notice” against non-FDA-approved compounded drugs mass-marketed as alternatives to approved ones. The green list adds pressure on supply, since ingredients from facilities the FDA hasn’t inspected or evaluated can be held at the border without physical examination.

Is compounded semaglutide safe?

Compounded drugs are not FDA-approved, and the FDA says they “are not reviewed by the agency for safety, effectiveness or quality prior to marketing” (FDA). The FDA also does not approve or license any pharmacy, so a claim of an “FDA-approved pharmacy” is false. Quality depends on the specific pharmacy that fills your prescription.

Compounded semaglutide has no FDA-approved label of its own. The Wegovy label, for FDA-approved semaglutide, carries a boxed warning for thyroid C-cell tumors and says not to use it with a personal or family history of medullary thyroid carcinoma or MEN 2. Its other warnings include pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration and aspiration risk under anesthesia.

Side effects are common. In Wegovy’s trials at 2.4 mg, nausea affected 44% of people vs 16% on placebo, diarrhea 30% vs 16%, vomiting 24% vs 6% and constipation 24% vs 11%. Ask a licensed clinician how these apply to you, whichever version you take.

Compounded vs FDA-approved semaglutide

Wegovy prices are from NovoCare Pharmacy. At the 39 programs we rank, as of October 2026, compounded semaglutide runs from $89 a month (altRx and Enhanced; LumiMeds’ $89 is a sale price, down from $189) to $299 (Willow, and MEDVi after a $179 first month). See the compounded GLP-1 guide and the Wegovy guide for more.

Compounded tablets

Some programs also sell compounded semaglutide as a tablet. WellPeps lists a daily tablet at $229 a month (not available to California residents), and Rila’s dissolvable tablets start at $217 a month with a 6-month commitment. These carry the same status as compounded injections: not FDA-approved. The FDA-approved semaglutide pill for weight loss is the Wegovy pill.

How to vet a compounded semaglutide provider

The FDA’s 2026 guidance for telehealth firms lists marketing it considers false or misleading. Treat any of these as a red flag:

• Branding that suggests the telehealth company makes the drug itself.
• Calling the drug a generic of an FDA-approved drug, or implying it matches one.
• Saying it is FDA-approved or has been evaluated for safety and effectiveness.
• Saying it is clinically proven to give the same result as an approved drug.
• Claiming an “FDA-approved” or “FDA-licensed” pharmacy.

On the positive side, look for a licensed clinician who reviews your health history before prescribing, a named pharmacy (Trillium, for example, shows your pharmacy choice and price before you start) and clear refund terms. Our compounded semaglutide rankings compare the programs we track, and our compounded tirzepatide price guide covers commitments and refunds.

Compounded or FDA-approved?

The price gap has narrowed. The Wegovy pill costs $149 a month at 1.5 mg and $299 at the 25 mg maintenance dose, against $89 to $299 for compounded semaglutide at the 39 programs we rank. If your plan covers Wegovy, the savings card can bring it to as little as $25 a month. Our guide to GLP-1s without insurance compares every cash option, and our match quiz can point you to programs that fit.

The bottom line

Compounded semaglutide is still legal in 2026, but only within the 503A rules, and it is not FDA-approved or reviewed by the FDA for safety, effectiveness or quality. Watch for sellers that blur that line, since the FDA has warned more than 70 of them. With the Wegovy pill now $149 to $299 a month, ask a licensed clinician whether an FDA-approved option fits your budget before choosing compounded.